Comparative Pharmacology
Head-to-head clinical analysis: AQUAPHYLLIN versus THEOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAPHYLLIN versus THEOBID.
AQUAPHYLLIN vs THEOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/mL). Max 600 mg/day unless serum levels monitored.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Neonates: 24-36 h; Children (1-9 y): 3-4 h; Adults (non-smokers): 6-12 h; Adults (smokers): 4-5 h; Hepatic cirrhosis: prolonged (up to 30 h); Heart failure: prolonged (up to 20 h).
Renal: 90-95% unchanged; biliary/fecal: <5%.
Renal (10% unchanged), hepatic metabolism (90%, primarily via CYP1A2 and CYP3A4); 20% excreted in feces as metabolites.
Category C
Category C
Bronchodilator
Bronchodilator